Acute myeloid leukemia (AML) is a malignant hematological disease with a poor prognosis. Standard therapy includes chemotherapy with/without subsequent stem cell transplantation which has several toxic side effects. In order to hide from the immune-system AML cells appear to manipulate immune cells in the bone marrow. It is unclear how this mechanism can be reversed. To understand the interaction of AML and immune cells in the human bone marrow, cell-specific gene patterns associated with treatment response or relapse will be decoded in this project. The aim is to determine mechanisms that support immunotherapy against AML and to find out which patients with intermediate cytogenetic/molecular risk are most likely to benefit from stem cell transplantation.

Here you can find further information.